Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Acquisition and option over Uranium concentrates

12 Nov 2010 11:30

For immediate release: 12 November 2010

Emerging Metals Limited ("EML", "Emerging Metals" or "the Company") Acquisition and option over Uranium concentrates

Emerging Metals Limited (AIM: EML), the mining company focused on minor and emerging metals, is pleased to announce that it has contracted for the physical delivery of 25,000lbs triuranium octocide ("U3O8") and has entered into an option agreement for the physical delivery of a further 200,000lbs U3O8.

The contracts are in line with the Company's investing policy approved by shareholders at its meeting of shareholders on 16 April 2010 which encompasses exposure to Investment Metals including but not limited to the acquisition of physical quantities of Investment Metals commodities.

The physical delivery contract is priced at US$58.00 for each and every pound of U3O8 delivered and is in respect of 25,000lbs U3O8. Delivery to a conversion facility in Canada is due on 17 January 2011 with cash payment (equivalent to £ 898,723 at £/$ 1.6134) by no later than 18 January 2011.

The option contract is in respect of 200,000lbs U3O8 for physical delivery by book transfer at a designated facility and expires on 31 January 2011. An option premium of US$500,000 (equivalent to £309,905 at £/$ 1.6134) is payable on 17 November 2010 and the additional option strike price is US$59.00 per pound U3O8, or a total US$11,800,000 (equivalent to £7,313,747 at £/$ 1.6134).

Stephen Dattels, Emerging Metals Co Chairman commented:

"Uranium pricing prospects remain strong. The ability for the Company to invest in physical quantities of investment metals as well as mining projects gives us the flexibility to capitalise on shorter term pricing movements with the objective of generating meaningful returns to shareholders. Whilst cash available for investments remains strong, we are confident this first physical commodity investment will rapidly demonstrate the value of our broader investing policy to shareholders."

-- Ends -- Contact details Emerging Metals Religare Capital Fox-Davies Capital GTH Limited Markets Limited Communications Denham Eke Peter Daniel Fox-Davies Toby Hall Trevelyan-Clark Christian Pickel Emily Staples

+44 (0) 1624 639396 +44 (0) 20 7444 +44 (0) 20 7936 +44 (0) 20 3103

0800 5200 3900

vendor
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.